Clinical Trial Update: 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a third-generation GD-2 CAR-T cell therapy with an iCaspase suicide safety switch for neuroblastoma; current status shows not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• GD-2 CAR-T (3rd generation) with iCaspase safety switch (3rd generation GD-2 CAR-T with iCaspase suicide switch)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Neuroblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING